Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 10:55 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2161–2184 of 33,151 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: placebo Clear all

Conditions: Glabellar Frown Lines
Interventions: AbobotulinumtoxinA dose level 1 or 2, placebo, AbobotulinumtoxinA dose 3, AbobotulinumtoxinA dose 4; Biological · Other
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 401 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 10
States / cities: Encino, California • Manhattan Beach, California • Vista, California + 7 more

Conditions: Pain Control
Interventions: TAP block using Bupivacaine 0.5%, TAP block using Bupivacaine 0.25%, TAP block using Normal Saline; Procedure
Lead sponsor: New York Presbyterian Brooklyn Methodist Hospital; Other
Eligibility: Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Sexual Dysfunction, Bipolar Disorder
Interventions: Maca Root, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Atopic Dermatitis
Interventions: GBR 830, Placebo; Biological
Lead sponsor: Ichnos Sciences SA; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 12
States / cities: Rogers, Arkansas • Los Angeles, California • San Diego, California + 9 more

Conditions: Genitourinary Syndrome of Menopause
Interventions: MonaLisa Touch; Device
Lead sponsor: Michigan Institution of Women's Health PC; Other
Eligibility: Female only
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Dearborn, Michigan

Conditions: Aspergillosis
Interventions: Voriconazole, micafungin; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Little Rock, Arkansas

Conditions: Vascular Stiffness, Endothelial Dysfunction, Diastolic Dysfunction
Interventions: Salsalate, Placebo (for salsalate); Drug
Lead sponsor: Gary L. Pierce; Other
Eligibility: 18 Years to 79 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Hypogonadism, Osteopenia, Osteoporosis
Interventions: Testosterone, Alendronate, Placebo Alendronate, Placebo Testosterone; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 60 Years to 85 Years · Male only
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Partial Thickness Rotator Cuff Tears
Interventions: TPX-115, Cryopreserving hyaluronic acid medium, Saline; Biological · Other · Drug
Lead sponsor: Tego Science, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: La Mesa, California • Deerfield Beach, Florida • Chicago, Illinois

Conditions: Diabetes Mellitus, Type 2
Interventions: Canagliflozin 100 mg, Canagliflozin 300 mg, Antihyperglycemic agent(s), Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 55 Years to 80 Years
Enrollment: 716 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 34
States / cities: Glendale, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 31 more

Conditions: Healthy Males, Male Contraceptive
Interventions: First Intervention (7 days), First Washout (7 days), Second Intervention (7 days), Third Intervention (7 days), Second wash-out period; Drug · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Macular Degeneration, Choroidal Neovascularization
Interventions: Verteporfin Photodynamic Therapy, Ranibizumab, Verteporfin Placebo, Ranibizumab Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 50 Years and older
Enrollment: 321 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 36
States / cities: Tucson, Arizona • Beverly Hills, California • Oakland, California + 33 more

Conditions: Salmonella
Interventions: CVD 1902, a Salmonella enterica Serovar Paratyphi A live, oral vaccine, Placebo; Biological · Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 45 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Attention Deficit Disorder With Hyperactivity
Interventions: clonidine, methylphenidate, placebo; Drug · Other
Lead sponsor: University of Cincinnati; Other
Eligibility: 7 Years to 12 Years
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2007
U.S. locations: 4
States / cities: Buffalo, New York • Rochester, New York • Cincinnati, Ohio + 1 more

Conditions: Neck Pain
Interventions: BEMER, OMT, Sham OMT + Sham BEMER; Device · Procedure
Lead sponsor: Lake Erie College of Osteopathic Medicine; Other
Eligibility: Not listed
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Bradenton, Florida

Conditions: Cutaneous Lupus Erythematosus (CLE), Systemic Lupus Erythematosus, SLE, SLE (Systemic Lupus), CLE
Interventions: VENT-03, Placebo; Drug
Lead sponsor: Ventus Therapeutics U.S., Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 15
States / cities: Beverly Hills, California • Clearwater, Florida • DeBary, Florida + 12 more

Conditions: Wheezing, Asthma in Children
Interventions: Soy isoflavone, matching placebo; Drug
Lead sponsor: Rajesh Kumar; Other
Eligibility: 2 Months to 12 Months
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Anxiety Disorder, Seizures, Epilepsy, Partial Epilepsy, Depression
Interventions: Buspirone, Placebo; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Non-alcoholic Steatohepatitis
Interventions: Semaglutide, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 1,205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 130
States / cities: Huntsville, Alabama • Chandler, Arizona • Peoria, Arizona + 100 more

Conditions: Insulin Resistance, Obesity
Interventions: INCB13739; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 2
States / cities: Beverly Hills, California • Chula Vista, California

Conditions: Methamphetamine Dependence, Substance Abuse, Methamphetamine Abuse
Interventions: Varenicline, Placebo; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Anthracycline Related Cardiotoxicity in Breast Cancer
Interventions: sulforaphane, Placebo Oral Tablet; Drug
Lead sponsor: Texas Tech University Health Sciences Center; Other
Eligibility: 18 Years to 89 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Adenomatous Polyp, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage I Colon Cancer, Stage I Rectal Cancer, Stage IIA Colon Cancer, Stage IIA Rectal Cancer, Stage IIB Colon Cancer, Stage IIB Rectal Cancer, Stage IIC Colon Cancer, Stage IIC Rectal Cancer, Stage IIIA Colon Cancer, Stage IIIA Rectal Cancer, Stage IIIB Colon Cancer, Stage IIIB Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Rectal Cancer
Interventions: erlotinib hydrochloride, placebo, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 3
States / cities: Long Beach, California • Orange, California • Chicago, Illinois

Conditions: Cerebral Adrenoleukodystrophy (cALD)
Interventions: Leriglitazone, Placebo; Drug
Lead sponsor: Minoryx Therapeutics, S.L.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 4
States / cities: Palo Alto, California • Baltimore, Maryland • Boston, Massachusetts + 1 more

Search by objective public record fields.

Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Glabellar Lines

Efficacy of TAP Block in Cesarean Section Patients

Study of Maca Root to Treat Sexual Dysfunction Associated With the Treatment Regimen for Bipolar Disorder in Females

To Assess the Safety and Activity of GBR 830, Compared to Placebo, in Adults With Moderate-to-severe Atopic Dermatitis

MonaLisa Touch Randomized Double-Blind Placebo Controlled Study

Trial of Combination Antifungal Therapy (Vori+Mica vs. Vori+Placebo) in Invasive Aspergillosis

Targeting Inflammation to Treat Cardiovascular Aging

Testosterone and Alendronate in Hypogonadal Men

Efficacy and Safety Study of TPX-115 on Partial-thickness Rotator Cuff Tear

A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus

Oral T7 Oral Testosterone in Man

Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization

Safety and Immunogenicity of CVD 1902 Oral Attenuated Vaccine to Prevent S. Paratyphi A Infection

Clonidine in Attention Deficit Hyperactivity Disorder (ADHD) in Children

Effects of Osteopathic Manipulative Treatment and Bio Electro-Magnetic Regulation Therapy on Neck Pain in Adults

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus

Soy Isoflavones For Inner City Infants At Risk For Asthma (SIRA) Study

Buspirone Therapy for Localized Epilepsy

Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)

A Study of the Effect of INCB013739 on Cortisone Reducing Enzyme Activity in Obese People Predisposed to Diabetes

Varenicline for Methamphetamine Dependence

Protective Effects of the Nutritional Supplement Sulforaphane on Doxorubicin-Associated Cardiac Dysfunction

Erlotinib Hydrochloride in Treating Patients With Stage I-III Colorectal Cancer or Adenoma

A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral Adrenoleukodystrophy